JP2013504590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504590A5 JP2013504590A5 JP2012528915A JP2012528915A JP2013504590A5 JP 2013504590 A5 JP2013504590 A5 JP 2013504590A5 JP 2012528915 A JP2012528915 A JP 2012528915A JP 2012528915 A JP2012528915 A JP 2012528915A JP 2013504590 A5 JP2013504590 A5 JP 2013504590A5
- Authority
- JP
- Japan
- Prior art keywords
- radioactive
- compound
- iodine
- group
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002285 radioactive effect Effects 0.000 claims 32
- -1 phospholipid compound Chemical class 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 229910052740 iodine Inorganic materials 0.000 claims 11
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 10
- 239000011630 iodine Substances 0.000 claims 10
- 239000008177 pharmaceutical agent Substances 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000007787 solid Substances 0.000 claims 4
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- ZOAIEFWMQLYMTF-UHFFFAOYSA-N 18-(4-iodophenyl)octadecyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound C[N+](C)(C)CCOP([O-])(=O)OCCCCCCCCCCCCCCCCCCC1=CC=C(I)C=C1 ZOAIEFWMQLYMTF-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 3
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24176209P | 2009-09-11 | 2009-09-11 | |
| US24175909P | 2009-09-11 | 2009-09-11 | |
| US61/241,759 | 2009-09-11 | ||
| US61/241,762 | 2009-09-11 | ||
| US30918710P | 2010-03-01 | 2010-03-01 | |
| US30921310P | 2010-03-01 | 2010-03-01 | |
| US61/309,213 | 2010-03-01 | ||
| US61/309,187 | 2010-03-01 | ||
| PCT/US2010/048351 WO2011031919A2 (en) | 2009-09-11 | 2010-09-10 | Non-radioactive phospholipid compounds, compositions, and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013504590A JP2013504590A (ja) | 2013-02-07 |
| JP2013504590A5 true JP2013504590A5 (enExample) | 2013-10-24 |
Family
ID=43730778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012528915A Pending JP2013504590A (ja) | 2009-09-11 | 2010-09-10 | 非放射性リン脂質化合物、組成物、及び使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20110064661A1 (enExample) |
| EP (1) | EP2475400A2 (enExample) |
| JP (1) | JP2013504590A (enExample) |
| RU (1) | RU2012114146A (enExample) |
| WO (1) | WO2011031919A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE437657T1 (de) * | 2004-03-02 | 2009-08-15 | Cellectar Inc | Phospholipid-analoga für die behandlung von krebs |
| US8540968B2 (en) * | 2004-03-02 | 2013-09-24 | Cellectar, Inc. | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof |
| SI2440253T1 (sl) * | 2009-06-12 | 2020-09-30 | Cellectar, Inc. | Alkil fosfolipidne spojine za zdravljenje raka in slikanje in detekcijo rakavih izvornih celic |
| WO2011031919A2 (en) * | 2009-09-11 | 2011-03-17 | Cellectar, Inc. | Non-radioactive phospholipid compounds, compositions, and methods of use |
| EA037519B1 (ru) * | 2014-11-17 | 2021-04-07 | Селлектар Байосайенсиз, Инк. | Аналоги простых эфиров фосфолипидов в качестве носителей лекарственных средств, нацеленных на раковые клетки |
| BR112022004482A2 (pt) * | 2019-09-12 | 2022-05-31 | Cellectar Biosciences Inc | Conjugados de éter fosfolipídico como veículos de fármacos direcionados ao câncer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4925649A (en) * | 1987-06-12 | 1990-05-15 | The University Of Michigan | Radioiodinated diacylglycerol analogues and methods of use |
| US5347030A (en) * | 1987-10-23 | 1994-09-13 | The Board Of Regents Of The University Of Michigan | Radioiodinated phospholipid ether analogues and methods of using same |
| US5087721A (en) * | 1987-10-23 | 1992-02-11 | The University Of Michigan | Radioiodinated phosphate esters |
| US4965391A (en) * | 1987-10-23 | 1990-10-23 | The University Of Michigan | Radioiodinated phospholipid ether analogues |
| US5369097A (en) * | 1991-04-25 | 1994-11-29 | The University Of British Columbia | Phosphonates as anti-cancer agents |
| US5783170A (en) * | 1991-11-27 | 1998-07-21 | Diatide, Inc. | Peptide-metal chelate conjugates |
| US5626654A (en) * | 1995-12-05 | 1997-05-06 | Xerox Corporation | Ink compositions containing liposomes |
| CA2276284C (en) * | 1996-12-04 | 2006-10-10 | The Regents Of The University Of Michigan | Radioiodinated phospholipid ether analogs and methods of using the same |
| US6255519B1 (en) * | 1996-12-04 | 2001-07-03 | Regents Of The University Of Michigan | Radioiodinated phospholipid ether analogs and methods of using the same |
| US6503478B2 (en) * | 1999-01-13 | 2003-01-07 | Lightouch Medical, Inc. | Chemically specific imaging of tissue |
| US7220539B1 (en) * | 2002-06-12 | 2007-05-22 | The Salk Institute For Biological Studies | Protein kinase B/Akt modulators and methods for the use thereof |
| US8540968B2 (en) * | 2004-03-02 | 2013-09-24 | Cellectar, Inc. | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof |
| ATE437657T1 (de) * | 2004-03-02 | 2009-08-15 | Cellectar Inc | Phospholipid-analoga für die behandlung von krebs |
| US7632644B2 (en) * | 2004-03-02 | 2009-12-15 | Cellectar, Inc. | Imaging and selective retention of phospholipid ether analogs |
| WO2005097158A1 (en) * | 2004-03-29 | 2005-10-20 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Amphipathic glycopeptides |
| CA2572398A1 (en) * | 2004-07-08 | 2006-02-09 | Cellectar, Llc | Virtual colonoscopy with radiolabeled phospholipid ether analogs |
| US20060115426A1 (en) * | 2004-08-11 | 2006-06-01 | Weichert Jamey P | Methods of detecting breast cancer, brain cancer, and pancreatic cancer |
| US7041859B1 (en) * | 2004-09-09 | 2006-05-09 | University Of Tennessee Research Foundation | Method for halogenating or radiohalogenating a chemical compound |
| JP2008545614A (ja) * | 2004-12-20 | 2008-12-18 | セレクター、リミテッド ライアビリティ カンパニー | 癌の検出および治療のためのリン脂質エーテル類似体 |
| CA2660778A1 (en) * | 2006-08-15 | 2009-01-08 | Cellectar, Inc. | Near infrared-fluorescence using phospholipid ether analog dyes in endoscopic applications |
| US7893286B2 (en) * | 2007-06-01 | 2011-02-22 | Cellectar, Inc. | Method for the synthesis of phospholipid ethers |
| SI2440253T1 (sl) * | 2009-06-12 | 2020-09-30 | Cellectar, Inc. | Alkil fosfolipidne spojine za zdravljenje raka in slikanje in detekcijo rakavih izvornih celic |
| WO2011031919A2 (en) * | 2009-09-11 | 2011-03-17 | Cellectar, Inc. | Non-radioactive phospholipid compounds, compositions, and methods of use |
| US20110064660A1 (en) * | 2009-09-11 | 2011-03-17 | Pinchuk Anatoly | Deuterated alkyl phospholipid compounds, compositions, and methods of use |
-
2010
- 2010-09-10 WO PCT/US2010/048351 patent/WO2011031919A2/en not_active Ceased
- 2010-09-10 JP JP2012528915A patent/JP2013504590A/ja active Pending
- 2010-09-10 RU RU2012114146/15A patent/RU2012114146A/ru unknown
- 2010-09-10 EP EP10816122A patent/EP2475400A2/en not_active Withdrawn
- 2010-09-10 US US12/879,167 patent/US20110064661A1/en not_active Abandoned
-
2012
- 2012-02-23 US US13/403,445 patent/US20120156133A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013504590A5 (enExample) | ||
| US20250295869A1 (en) | Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer | |
| JP2020514311A5 (enExample) | ||
| US8623322B2 (en) | Non-invasive diagnostic agents and methods of diagnosing infectious disease | |
| JP2011529919A5 (enExample) | ||
| JP2014510729A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2011517683A5 (enExample) | ||
| JP2021502368A (ja) | 免疫療法に対する抗腫瘍免疫応答を促進するための標的化放射線療法（ｔｒｔ）の使用 | |
| RU2012134510A (ru) | Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников | |
| JP2012522841A5 (enExample) | ||
| RU2012114146A (ru) | Нерадиоактивные фосфолипидные соединения, композиции и способы их применения | |
| CA3031776A1 (en) | Targeted radiotherapy chelates for in situ immune modulated cancer vaccination | |
| JP2008500366A5 (enExample) | ||
| JP2010514734A (ja) | 腸障害の治療のためのイソソルビドモノニトレート誘導体 | |
| WO2021001360A1 (en) | Prostate specific membrane antigen (psma) ligands and uses thereof | |
| RU2007104176A (ru) | Синтез и применение (-)-бета-элемена, (-)-бета-элеменала, (-)-бета-элеменола, фторида (-)-бета-элемена и их аналогов, а также промежуточных продуктов и композитов | |
| Fonge et al. | Evaluation of tumor affinity of mono‐[123I] iodohypericin and mono‐[123I] iodoprotohypericin in a mouse model with a RIF‐1 tumor | |
| JP2013525290A5 (enExample) | ||
| Wang et al. | Combination treatment with bortezomib and thiostrepton is effective against tumor formation in mouse models of DEN/PB-induced liver carcinogenesis | |
| JP2016501884A5 (enExample) | ||
| RU2010120810A (ru) | Гидратированные кристаллические сложные эфиры камптотецина для лечения рака | |
| JP2011500841A5 (enExample) | ||
| CA2569739C (en) | Antitumor effect potentiator, antitumor preparation, and method for treating cancer | |
| WO2023202730A2 (zh) | 放射性伊文思蓝衍生物药物水溶液及其制备方法和用途 |